{
  "source": "PA-Notification-Voydeya.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1444-2\nProgram Prior Authorization/Notification\nMedication Voydeya™ (danicopan)\nP&T Approval Date 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nVoydeya (danicopan) is a complement factor D inhibitor indicated as add-on therapy to\nUltomiris (ravulizumab) or eculizumab for the treatment of extravascular hemolysis (EVH) in\nadults with paroxysmal nocturnal hemoglobinuria (PNH).1\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Voydeya will be approved based on all of the following criteria:\na. Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH)\n-AND-\nb. Patient is currently receiving complement protein C5 inhibitor eculizumab or\nUltomiris (ravulizumab)\n-AND-\nc. Patient is experiencing extravascular hemolysis (EVH) while on complement protein\nC5 inhibitor eculizumab or Ultomiris (ravulizumab)\n-AND-\nd. Patient will continue to receive complement protein C5 inhibitor eculizumab or\nUltomiris (ravulizumab)\n-AND-\ne. Patient is not receiving Voydeya in combination with a complement protein C3\ninhibitor [e.g., Empaveli (Pegcetacoplan)] or a complement factor B inhibitor [e.g.,\nFabhalta (iptacopan)] used for the treatment of PNH\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Voydeya will be approved based on all of the following criteria:\n© 2025 UnitedHealthcare Services Inc.\n1\na. Documentation of positive clinical response to Voydeya therapy [e.g., decrease in\nextravascular hemolysis (EVH), increased or stabilization of hemoglobin levels,\nreduction in transfusions, improvement in hemolysis, etc.]\n-AND-\nb. Patient continues to receive Voydeya in combination with complement protein C5\ninhibitor eculizumab or Ultomiris (ravulizumab) for PNH\n-AND-\nc. Patient is not receiving Voydeya in combination with a complement protein C3\ninhibitor [e.g., Empaveli (Pegcetacoplan)] or a complement factor B inhibitor [e.g.,\nFabhalta (iptacopan)] used for the treatment of PNH\nAuthorization wi",
    "ya in combination with a complement protein C3\ninhibitor [e.g., Empaveli (Pegcetacoplan)] or a complement factor B inhibitor [e.g.,\nFabhalta (iptacopan)] used for the treatment of PNH\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may also be in place.\n4. References:\n1. Vodeya [package insert]. Boston, Massachusetts: Alexion Pharmaceuticals, Inc.; March 2024.\nProgram Prior Authorization/Notification - VoydeyaTM (danicopan)\nChange Control\n5/2024 New program\n5/2025 Annual review. Updated list of C5 inhibitors by removing trade name of\nSoliris from eculizumab.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}